In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

antiviral agent that specifically inhibits influenza viruses a and b, including the highly pathogenic subtypes a (h1n1) pdm09 and a (h5n1). according to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes.

Therapeutic efficacy in influenza is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with influenza.

The drug refers to low-toxic drugs, does not adversely affect the human body when used in recommended doses.

Pharmacokinetics The drug is rapidly absorbed in the digestive tract. Cmax in blood plasma is achieved when taken at a dose of 50 mg after 1.2 hours, at a dose of 100 mg - 1.5 hours after administration. T½ is 17-21 hours. About 40% of the drug is excreted unchanged: with feces (38.9%) and urine (0.12%). During the first day, 90% of the dose taken is excreted.


Prevention and treatment of influenza a and b.


Apply to adults. take orally before eating. single dose is 200 mg.

For prevention:

in direct contact with patients with influenza: 200 mg once a day for 10-14 days;

during the flu epidemic: 200 mg 2 times a week for 3 weeks.

For the treatment of influenza: 200 mg 4 times a day (every 6 hours) for 5 days.

The maximum daily dose is 800 mg.


Hypersensitivity to the active substance or other components of the drug.

Side effects

Disorders from the immune system: hypersensitivity reactions, including redness of the skin, itching, rash, urticaria, angioedema.

Changes in the digestive tract, including heartburn, a feeling of heaviness in the epigastric region, vomiting.

special instructions

Use during pregnancy and lactation. the safety of use during pregnancy and lactation has not been studied enough.

Children. Do not use in children.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. At recommended doses, it does not affect the reaction rate when driving vehicles or working with other mechanisms.


When the drug interacted with other drugs, no negative effects were detected.


Not marked.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.

Tags: Immustat® [Umifenovir hydrochloride]